Evidence map›Paper›PMID 38778606›Full record

ArticleCurrent cancer drug targets2025

LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression.

Dute Gao, Huahu Guo, Zhaochen Liu, Liang Bao, Suxin Li, Yunchao Wang, Jiange Qiu, Binghua Jiang, Xiaowei Dang

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dute GaoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huahu GuoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhaochen LiuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liang BaoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Suxin LiDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yunchao WangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jiange QiuAcademy of Medical Science, Zhengzhou University, Zhengzhou, China.
Binghua JiangAcademy of Medical Science, Zhengzhou University, Zhengzhou, China.
Xiaowei DangDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

Henan Provincial Science and Natural Science Foundation 232300420232Key Projects of Institutions of Higher Learning in Henan Province 21A320062National Natural Science Foundation of China 82002560
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most aggressive malignancies in the world. Lamin B1 (LMNB1) is a key component of the nuclear skeleton structure. Recent studies have found that LMNB1 is overexpressed in tumor tissues and is associated with the prognosis of patients. However, the underlying mechanism remains unclear in HCC.

objectiveThis study aims to explore the clinical significance and molecular mechanisms of LMNB1 in HCC.

methodsThe expression level of LMNB1 and its clinical values were analyzed with public databases, and the level of LMNB1 in HCC tissues and adjacent normal tissues was confirmed by qRT-PCR and IHC. Functional assays were conducted to explore the impact of LMNB1 knockdown on cell proliferation both

resultsLMNB1 was found to be overexpressed in HCC and correlated with the pathological stage and unfavorable prognosis. Functional assays demonstrated that LMNB1 promotes HCC proliferation both

conclusionsLMNB1 emerged as a promising therapeutic target and prognostic biomarker for HCC, with its expression showing a correlation with several immune infiltration cell markers.

Indexed as

Carcinoma, HepatocellularCyclin-Dependent Kinase Inhibitor p21Lamin Type BLiver NeoplasmsAnimalsBiomarkers, TumorCell CycleCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeBiomarkers, TumorCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Lamin Type BCDKN1Acell cyclehepatocellular carcinomaimmune infiltration.LMNB1proliferation

Identifiers

PMID38778606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.